CREDENCE and CARMELINA
Tuesday 11 June: 7:30–9:30
Presenters: Rajiv Agarwal, MD, MBBS, FASN, BRCU; Meg Jardine, MD, PhD; Bruce Neal, MB, ChB, PhD; Kenneth W. Mahaffey, MD, PhD; Bernard Zinman, CM, MD.
The CREDENCE primary findings, published in April this year, showed that the sodium-glucose cotransporter 2 (SGLT2) inhibitor canagliflozin significantly reduced the risk for renal failure and cardiovascular disease in people with type 2 diabetes and chronic kidney disease.
The researchers will present these results in full, along with an analysis of outcomes by baseline cardiovascular disease.
More on the CREDENCE trial
- News story | Canagliflozin may offer renal protection in people with type 2 diabetes and CKD
- Clinical trial commentary | WATCH: Diabetes expert commentary on the CREDENCE trial
- Clinical trial commentary | LISTEN: Researcher comment on the CREDENCE trial
- Clinical trial commentary | LISTEN: A primary care diabetes expert on the CREDENCE trial
- Clinical trial commentary | LISTEN: A nephrologist discusses the CREDENCE trial
- Ask the expert | WATCH: Nephrologist Katherine Tuttle shares practice tips with Jay Shubrook
Update 06-12-2019 | CARMELINA findings confirmed in highest CV risk subgroups
Presenters: Steven E. Kahn, MB, ChB; Nikolaus Marx, MD, FESC, FAHA; Darren K. McGuire, MD, MHSc; Robert D. Toto, MD; Christoph Wanner, MD; Mark E. Cooper, MBBS, PhD.
The CARMELINA trial was powered to detect cardioprotective effects of the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, but it showed only that it was noninferior to placebo. The researchers will present new renal analyses at this year's ADA.
The CAROLINA trial, also being presented at ADA, is reporting the results of a head-to-head comparison of the cardiovascular safety/efficacy of linagliptin and glimepiride.
More on the CARMELINA trial
- News story | Favorable long-term cardiovascular safety profile of linagliptin in type 2 diabetes
- Quick guide | Round-up of the DPP-4 inhibitor CV outcome trials